
Two new millipede species discovered in Western Ghats regions of Maharashtra and Kerala
Pune: Two new species of millipedes have been added to India's arthropod diversity after their discovery in Western Ghats regions, namely Karad in Maharashtra and in Kerala.
The discovery of the two species — named Polydrepanum xiphosum and Polydrepanum spinatum — by a team of Indian scientists was published in the New Zealand-based journal Zootaxa on May 24 this year.
Tired of too many ads? go ad free now
The development takes the count of India's millipede species to 270, over 70% of which are endemic.
Both newly found species belong to the genus Polydrepanum in the Paradoxosomatidae family. Now, the genus includes six recognised and extant species — all exclusive to the Western Ghats, which is a biodiversity hotspot.
This discovery highlights the importance of conserving microhabitats within the Western Ghats, which is crucial for sustaining unique and ecologically significant species, said researchers.
The study stated: "The findings highlight the region's status as a global biodiversity hotspot and the importance of its often-overlooked soil-dwelling invertebrates."
Research team member Dr Aparna Sureshchandra Kalawate from the Zoological Survey of India (ZSI), Pune, told TOI, "This discovery took almost five months of rigorous work, from field collection activity in Karad and parts of Kerala to comparing them with existing taxonomic records.
It became evident they didn't match any known species. We believe there may be many more such species awaiting discovery in the Ghats.
"
Besides Kalawate, the team comprised Dr Sudhikumar Ambalaparambil, head of the zoology department at Christ College, Irinjalakuda (Kerala), and research scholars Muhsina Musthafa (Christ College) and Pooja Misal (Shivaji University, Kolhapur).
The team is currently collecting more samples and furthering their study to find different species in the Western Ghats.
Tired of too many ads? go ad free now
Elaborating on the importance of the tiny creatures they are studying, Kalawate shared, "Millipedes, though small and often unseen, play a crucial role in the ecosystem. As decomposers, they feed on decaying plant matter and enhance soil quality by stimulating microbial activity and releasing essential nutrients like nitrogen into the soil."
Millipedes are vital components of the food chain for other invertebrates as well, said the researcher, adding, "Despite their importance, millipedes are under threat due to increasing soil pollution, land-use changes, concrete encroachment, and the overuse of fertilisers and industrial waste."
The research team shared, "Millipedes are the largest macro arthropods and also known as 'indicators of environmental alteration or conditions'. They have an important role in the ecosystem, especially in the food chain, as a 'decomposer'. Although only 10% of total decomposition of plant litter within an ecosystem takes place through millipedes, their feeding enhances microbial activities, resulting in the breakdown of litter up to 90%.
"
Millipedes are typically found in moist environments, such as beneath decaying leaves, in the soil, and in damp areas.
The scientists emphasised the need to conserve moist microhabitats in the Western Ghats — leaf litter, decaying logs, and forest soil — that are essential for the survival of these non-venomous, harmless invertebrates.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
43 minutes ago
- Time of India
Hyderabad cardiologist gets US patent for multi-functional cardiac occluder
File photo: Dr Nageswara Rao Koneti HYDERABAD: An innovative device that can fix various types of cardiac defects, designed by Hyderabad-based Dr Nageswara Rao Koneti, who heads the Cardiology Division at Rainbow Children's Heart Institute, has been granted a US patent. Called KONAR-MF Occluder, the multi-functional device can close septal defects in children and adults. It is a double umbrella disc device made of nitinol, a biocompatible nickel and titanium alloy, and is stretchable up to 15 mm. It can treat various conditions, including ventricular septal defects, coronary arteriovenous fistulas, and paravalvular leaks. The device has already been patented in India, Europe (European Commission), Euro-African countries, and South Korea. The multifunctional device not only fixes multiple types of cardiac lesions but also makes advanced cardiac care more affordable for patients in India, as it costs just Rs 50,000 in India compared to Rs 1.2 lakh in Pakistan and Rs 2.5–6 lakhs in other parts of Asia and Europe, said Dr Koneti. Terming this as a proud moment for Indian science, Dr Koneti said: "This US patent validates that innovations from India can meet global standards. It took us over six years to develop the device, and we applied for CE approval in 2018.' He said the US patent now paves the way for a US FDA (US Food and Drug Administration) approval for the device, which has already been implanted in about 10-15 patients in the US on compassionate grounds. "But we can also do clinical trials in the US if required," said Dr Koneti, who is a paediatric interventional cardiologist. He pointed out that the device has already demonstrated its safety and efficacy through over 20 peer-reviewed studies, and over 10,000 of these devices have already been implanted in patients in over 90 countries across Asia, Europe, Latin America, and Africa since the device got CE approval in 2018. The device is manufactured by LifeTech Scientific of China. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


India Today
2 hours ago
- India Today
Isro chief reviews prep ahead of Indian astronaut's launch to space
With just days remaining until the launch of the landmark Axiom Mission 4 (Ax-4), Indian Space Research Organisation (Isro) chief V Narayanan visited Axiom Space's Houston facilities.,Axiom Space will launch Indian astronaut Shubhanshu Shukla on 14-day mission to the Space Station on June visit by the Indian space agency chief focused on Axiom's manufacturing and technical capabilities, as both organisations prepare for India's return to human spaceflight after more than four decades. advertisement The Ax-4 mission, now scheduled for launch on June 10, 2025, will see Group Captain Shubhanshu Shukla become only the second Indian to travel to space, and the first to visit the International Space Station (ISS).Shukla, serving as mission pilot, will join commander Peggy Whitson (USA), and mission specialists Sawosz Uznaski-Winiewski (Poland) and Tibor Kapu (Hungary) for a 14-day scientific mission aboard the the Isro Chairman's tour, Axiom Space leadership reiterated their commitment to supporting Isro's space ambitions. Days away from our historic #Ax4 human spaceflight mission, the ISRO Chairman visited the full complement of Axiom Space facilities with a focus on our team's manufacturing and technical expertise. We are committed to supporting ISRO's space endeavors Ax-4 and beyond! Axiom Space (@Axiom_Space) June 4, 2025The Ax-4 mission will conduct around 60 scientific studies involving 31 countries, with Isro selecting seven microgravity experiments in fields such as agriculture, food science, and human efforts are expected to provide critical experience for India's upcoming Gaganyaan mission and future space station Isro Chairman's visit marks a significant milestone in India's growing role in global space exploration and signals a new era of public-private collaboration in advancing human spaceflight. Must Watch


Indian Express
2 hours ago
- Indian Express
A father-son legacy of Padma honors and pioneering scientific research
Written by Siddhi Patil, Dr Chetan Eknath Chitnis, a globally renowned Indian scientist, has dedicated his life to combating malaria, a persistent global health challenge claiming countless lives annually. His groundbreaking work in malaria vaccine development has earned him the prestigious Padma Shri this year, alongside awards like the Shanti Swarup Bhatnagar Award and the Infosys Prize. Remarkably, Dr. Chitnis shares a rare distinction with his father, Eknath Vasant Chitnis, a Padma Bhushan recipient (1985) and a founding member of the Indian Space Research Organisation (ISRO). This rare father-son duo's Padma honors reflect a deep family legacy of scientific excellence, with both making transformative contributions to their respective fields. Dr. Chitnis's journey in medical research is deeply rooted in his upbringing. His father, a distinguished space scientist and former director of ISRO's Space Application Centre, instilled a passion for dedicated work. 'My father taught me that true commitment means loving what you do, no matter the hours,' Dr. Chitnis recalls. While he initially pursued physics, inspired by his father's rigor, it was his mother, a biochemist focused on cancer research, who steered him toward biology. This pivot led him to lead the Malaria Parasite Biology and Vaccines Unit at Institut Pasteur in Paris, where he drives innovative vaccine research to curb malaria's devastating impact. Pune holds a special place in Dr. Chitnis's heart. Childhood summers spent at his grandparents' home in Deccan Gymkhana, exploring nearby hills with cousins, evoke memories of a serene, green Pune. His parents' decision to settle in the city post-retirement deepened his connection. Today, as Pune evolves into a bustling hub of innovation, Dr. Chitnis is eager to engage with its academic and research communities, blending personal nostalgia with professional aspirations. From IIT Bombay to UC Berkeley, the National Institutes of Health, and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi, Dr. Chitnis's career spans continents. His work at ICGEB, supported by robust government backing, laid the foundation for his current efforts in Paris. A significant breakthrough came during the COVID-19 pandemic when delayed vaccine trials at Oxford revealed that a 14-month gap between doses reduced malaria parasite growth—an unexpected finding inspired by similar COVID-19 vaccine insights. This discovery, coupled with advancements in mRNA technology, fuels his cautious optimism for future malaria solutions. The Padma Shri holds deep significance for Dr. Chitnis. 'Being recognised by my homeland, even after a decade abroad, is humbling,' he says. He views the award as a tribute to his team's collective efforts and a call to continue serving society.